TBA
TTPH

Tower Bridge Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Tower Bridge Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-750
Closed -$7.21K – 220
2019
Q2 		$7.21K Hold
750
– – ﹤0.01% 211
2019
Q1 		$20.1K Hold
750
– – ﹤0.01% 205
2018
Q4 		$16.9K Buy
+750
New +$29.3K ﹤0.01% 195

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tower Bridge Advisors's TTPH Position: Q3 2019 in Review

Tower Bridge Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 750 shares — an estimated $7.21K sold.

Tower Bridge Advisors first reported a position in TTPH in Q4 2018 and held it in 3 quarters. The position peaked at $20.1K in Q1 2019. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Tower Bridge Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Tower Bridge Advisors sold 750 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $7.21K.
  • Tower Bridge Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
  • Tower Bridge Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $20.1K in Q1 2019.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Tower Bridge Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.